Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Roche unveiled a strong Q2 performance driven by new medicines and continued strong growth from its diagnostics division but analysts were most keen for clues on plans for gantenerumab, now in Phase III studies for Alzheimer’s disease.
Management tried to sidestep controversy around the approval of Aduhelm and said it remains confident the drug will be reimbursed.
PureTech is among the very first companies to attempt to treat long Covid and hopes its anti-fibrosis drug can aid patients’ recovery
Sweden-based Anocca AB will use a just completed $47m Series B financing to advance its industrialized cellular biology platform and pipeline of TCR-T cellular therapies into Phase I/IIa oncology clinical trials, its CEO tells Scrip.
The company aims to overcome drawbacks of existing gene therapy platforms, starting in ocular and CNS diseases.
After immuno-oncology, mRNA is fast becoming a hot area in China as a flurry of biotechs from I-Mab to Kangtai partner with a little-known developer.
Doctors and patients need to be persuaded of the benefits of switching from familiar oral therapies to Cabenuva, the once-monthly anti-HIV injection.
In search of a differentiated approach, candidate aims to boostT-cell immune responses via a subcutaneous and oral vaccine combination.
South Korea’s Ildong Pharmaceutical has begun a major transformation from an OTC-focused firm to an innovative R&D-based operation that aims to compete with global big pharma rivals, helped by both internal and external alliances, its R&D head says in an interview with Scrip.
Poxel’s shift to new therapeutic areas may be necessary despite Japan’s approval for its diabetes drug. Twymeeg looks set to be hamstrung by placebo-controlled studies without outcomes data.
The unprecedented deal between two public Chinese biotechs, Innovent Biologics and Ascentage Pharma, potentially provides an opening for more such mega-million dollar deals to come.
AstraZeneca and FibroGen hit another safety roadblock with roxadustat, while GSK is hoping it might catch up with its rivals in the US.
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.